Search Resources (English): Regulatory agencies, Women and Health Protection (WHP)

4 results

Results

Women and adverse drug reactions: reporting in the Canadian context  
http://www.whp-apsf.ca/pdf/fullerReport.pdf
Provides an overview of how Canada's program for reporting Adverse Drug Reactions (ADRs) supports-or doesn't support-an effective women's health strategy related to prescription drug use. (See Details)
Published: 2002, 2003
International harmonisation of pharmaceuticals: key issues of concern for public health  
http://www.whp-apsf.ca/en/documents/harmon.html
Focuses on the activities and implications of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Identifies specific areas of concern for public health and the public interest in the realisation of health. (See Details)
Published: 2001
Complaint letter to Health Canada: Pfizer "toe-tag" ad  
http://www.whp-apsf.ca/en/documents/pfizerCampaign.html

This letter to Health Canada argues that the pharmaceutical manufacturer, Pfizer, has been running television ads with misleading information on cardiovascular risks and using Canadian's fear of death from heart disease in order to promote sales of its product.  It urges Health Canada to take regulatory action on this campaign.

 (See Details)
Published: January 2004
Complaint letter to Minister Tony Clement regarding DTCA of celebrex  
http://www.whp-apsf.ca/en/documents/celebrex_letter.html

This letter raises concerns about the risks to public health of an advertisement for a prescription drug, Celebrex (celecoxib), that aired on Canadian television. The letter asks Minister Tony Clement to take immediate regulatory action to stop this advertising campaign and to impose sanctions on the sponsor, Pfizer, to prevent future violations.

 (See Details)
Published: March 14, 2006